TOLREMO therapeutics: Funding, Investors & Team (Sep 2026)
TOLREMO therapeutics focuses on designing small molecules that specifically target unique pathways in cancer cells that make them resistant to drugs. By eradicating these drug-resistant cancer cells, the company enables doctors to provide personalized therapies that effectively prolong the lives of cancer patients.
TOLREMO therapeutics has raised $3.8M across 1 funding round on record, the most recent a Series A of $3.8M announced in Sep 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
TOLREMO therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2023.
TOLREMO therapeutics Funding Rounds
TOLREMO therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
TOLREMO therapeutics Funding Compared to Other Biotechnology Startups
TOLREMO therapeutics' latest round of $3.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TOLREMO therapeutics in Biotechnology and Zurich
Companies Similar to TOLREMO therapeutics
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
TOLREMO therapeutics Funding FAQs
What does TOLREMO therapeutics do?
TOLREMO therapeutics focuses on designing small molecules that specifically target unique pathways in cancer cells that make them resistant to drugs. By eradicating these drug-resistant cancer cells, the company enables doctors to provide personalized therapies that effectively prolong the lives of cancer patients.
How much funding has TOLREMO therapeutics raised?
TOLREMO therapeutics has raised $3.8M across 1 round on record. The most recent is a Series A of $3.8M announced in Sep 2023.
When did TOLREMO therapeutics last raise funding?
TOLREMO therapeutics' most recent funding round on record is a Series A of $3.8M, announced in Sep 2023.
Who is the CEO of TOLREMO therapeutics?
Stefanie Fluckiger Mangual is listed as CEO at TOLREMO therapeutics.
Where is TOLREMO therapeutics headquartered?
TOLREMO therapeutics is based in Zurich, Switzerland.
How many employees does TOLREMO therapeutics have?
TOLREMO therapeutics is in the 1-10 employee band.
How does TOLREMO therapeutics' funding compare to other Biotechnology startups?
TOLREMO therapeutics' latest round of $3.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's TOLREMO therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TOLREMO therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.